abstract: It is well known that human embryonic stem cells (hESCs) frequently acquire recurrent chromosomal abnormalities, very reminiscent of those found in cancerous cells. Given the parallels between cancer and stem cell biology, we set out to investigate the occurrence of a common form of genome instability in tumors, namely microsatellite instability (MSI), in hESCs. MSI is caused by a deficiency in mismatch repair (MMR) genes, which leads to the accumulation of mutations during DNA replication. In this study, we analyzed up to 122 microsatellites in a total of 10 hESC lines, for 1-11 different passages, ranging from passage 7 to passage 334. In two lines, this revealed that two microsatellites had altered allelic patterns. Small-pool PCR for several microsatellites and testing of the Bethesda panel microsatellites (commonly used in cancer studies) revealed that, whilst MSI is common in all tested lines, it occurs at a very low and variable frequency, ranging from 1 to 20% of the total number of alleles. In cancerous cells, MSI leads to multiple large shifts in allele sizes within the majority of the cells, while hESCs show small changes in a minority of the cells. Since these genetic alterations do not consistently take over the culture, we assume that they are not concurrent with a selective advantage as it is in tumors. Finally, the MMR genes showed a very variable gene expression that could not be correlated with the variable (low) levels of MSI in the different hESC lines.
Introduction
Human embryonic stem cells (hESCs) are capable of unlimited selfrenewal and differentiation into all cell types of the human body. They are therefore considered as a potential cell source for regenerative medicine (Thomson et al., 1998; Passier, 2003; Josephson et al., 2006) and as valuable research models for human development and disease (Friedrich Ben-Nun and Benvenisty, 2006; Beqqali et al., 2009; Biancotti et al., 2010) . However, it is known that the genome and epigenome of hESCs are prone to acquire abnormalities during in vitro culture (reviewed in Lund et al., 2012; Nguyen et al., 2012) , and that they carry numerous deletions in their mitochondrial genome (Van Haute et al., 2013) . A number of these abnormalities are highly recurrent, such as gains of 20q11.21 and deletions of 18q (Spits et al., 2008; Amps et al., 2011) , probably due to a selective advantage that they confer to the cell culture (Avery et al., 2013; Nguyen et al., 2014) . Interestingly, several of these mutations are commonly found in human cancers (Beroukhim et al., 2010; Niini et al., 2011; Tabach et al., 2011; The Cancer Genome Atlas Network, 2012; Xie et al., 2012) , highlighting the similarities between cancer cells and hESCs. Moreover, the phenotype of these mutant cells is frequently closer to that of cancer cells than to genetically normal hESCs with an increased expression of oncogenes and decreased expression of differentiation-related genes (Yangexpansion of cancer cells with MMR deficiency, uncorrected errors accumulate and lead to the progressive shortening or expansion of the microsatellite sequences, resulting in the appearance of new shorter or longer alleles compared with those found in the normal (non-cancerous) cells of the same individual (Thibodeau et al., 1993; Boland and Goel, 2005) .
MSI is found in 15% of colorectal (Aaltonen et al., 1993; Thibodeau et al., 1993) , gastric and endometrial cancers and in lower frequencies in other tumors (Hudler, 2012) . A standard panel of microsatellites, including mononucleotide (BAT26 and BAT25) and dinucleotide (D2S123, D5S346 and D17S250) repeats, has been recommended for MSI testing in cancer (Bethesda Guidelines; Boland et al., 1998) . Based on the number of microsatellites displaying instability, three groups of tumors are defined: those with at least 30% of the microsatellites showing instability (MSI-high, MSI-H); those with no more than 30% of the microsatellites showing instability (MSI-low, MSI-L) and those that show no instability (MSI-stable, MSS) (Boland et al., 1998; Findeisen et al., 2005) .
In MSI-H tumors, MSI frequently affects microsatellite sequences present in the coding region of critical growth regulatory and/or cancerrelated genes, resulting in a frame shift mutation that renders the protein inactive, driving a multi-step carcinogenesis. A comprehensive search using a genetic database for coding microsatellites and subsequent colorectal tumor analysis identified 9 genes that are mutated in .20% of the tumors: TGFBR2, BAX, MSH3, ACVR2, SEC63, AIM2, NDUFC2, KIAA0977 and PA2G4/EBP1 (Mori et al., 2001) . For example, 85% of colorectal tumors with MSI-H display instability of the repeat of 10 adenines in the TGFBR2 gene, causing the inactivation of this receptor and leading the cells to escape the growth-suppressive effects of the TGF-1 (Parsons et al., 1995) . Similarly, BAX, a pro-apoptotic gene, contains a polyguanine tract that shows frame shift mutations in 50% of MSI-H colorectal tumors, resulting in silencing of this gene and immortalization of these cells (Rampino, 1997; Boland and Goel, 2011) .
In this study, we initially found altered patterns in several microsatellites in two of our hESC lines. Given the striking similarities in genome instability between hESCs and cancerous cells, we set to investigate if these changes were due to MSI and if this was caused by MMR inactivation. For this, we screened a large number of our lines using the microsatellites suggested by the Bethesda guidelines, studied the frequency of abnormal alleles in several of our lines by small-pool PCR and investigated the expression of a set of MMR genes at the mRNA and protein levels.
Materials and Methods

Culture of hESC
All Vrije Universiteit Brussel (VUB) hESC lines were derived and characterized as previously described (Mateizel et al., 2006 Geens et al., 2009) , and are available upon request. Human ESC colonies were grown on inactivated mouse embryonic fibroblast (MEF) feeder layers at 378C in 5% CO 2 and physiological oxygen levels, using a standard hESC medium: KnockOut Dulbecco's modified Eagle's medium (KO DMEM; Invitrogen, Carlsbad, USA) containing 20% (v/v) KnockOut TM serum replacement (SR, Invitrogen), 2 mM glutamine (Invitrogen), 1% non-essential amino acids (Invitrogen), 0.1 mM b-mercapto-ethanol (Sigma-Aldrich, Schnelldorf, Germany), penicillin/streptomycin 100 U/ml (Invitrogen) and 4 ng/ml human recombinant basic fibroblast growth factor (Invitrogen). Human ESC colonies were passaged in clumps by mechanical slicing every 5 -6 days. Samples were collected from 1 to 11 different passages, ranging from passage 7 to passage 334 (Supplementary data, Table SIII shows an overview of all samples tested).
Creation of clonal hESC lines from single cells
Human ESCs were pre-incubated with 10 mM of Rho-associated kinase (ROCK) inhibitor, Y-27632 (Y05031MG, Sigma-Aldrich, water soluble) for 1 h before detaching from the feeder layer. Single hESCs were then collected using non-enzymatic cell dissociation solution (C5914, Sigma-Aldrich). The cell suspension was passed through a 40 mm cell strainer (BD Falcon, BD Biosciences, 9320 Erembodegem, Belgium) to remove remaining clumps and pelleted by centrifugation at 115g for 5 min. DNA, RNA extraction and cDNA synthesis
Genomic DNA was extracted using phenol and a mixture of 24 parts of chloroform to one part of 2-propanol (v/v). Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Solona, Sweden) following the manufacturer's instructions. Reverse transcription was performed using the FirstStrand cDNA Synthesis Kit (GE Healthcare, Buckinghamshire, UK) following the manufacturer's protocol.
Analysis of the chromosomal content by array-based comparative genomic hybridization (CGH)
Oligonucleotide array analysis (Human Genome oligo array-CGH 44K, Agilent, Santa Clara, CA, USA) was carried out following the manufacturer's instructions with minor modifications, as previously described (Buysse et al., 2009) . As reference, genomic DNA extracted from peripheral blood of male or female donors was used. Briefly, both test and reference genomic DNA (400 ng each) were labeled with Cy3 or Cy5 (BioPrime Array CGH Genomic Labeling System, Invitrogen) and subsequently purified by precipitation. After 24 h of hybridization at 658C, microarrays were washed and scanned by an Agilent microarray scanner. The scan images were processed with the Feature Extraction Software 10.1 (Agilent), and further analyzed and visualized using the arrayCGHbase software (http://medgen.ugent.be/ arraycghbase/).
Microsatellite analysis
Multiplex PCR
Depending on the label of the primer (HEX or FAM) and the length of the amplified fragments, the microsatellites were divided into different groups containing two, three or four primer pairs (Eurogentec, Seraing, Belgium). The primers sequences are listed in the Supplementary data, Table SI . In a final volume of 25 ml, 30 ng of purified genomic DNA was mixed with 12.5 ml PCR Master Mix (Qiagen w Multiplex, Qiagen) and 0.4 mM of each of the primer pairs (Integrated DNA Technologies, IDT) for the selected microsatellites. Following cycling parameters were applied: 5 min at 948C; 30 cycles of 30 s at 948C, 90 s at 588C, 30 s at 728C and final extension at 728C for 10 min. Multiplex PCR was also carried out for the standard Bethesda panel (as listed in Supplementary data, Table SII) as previously described (Imai and Yamamoto, 2008) following the same protocol.
Small-pool PCR
For those samples in which MSI was detected, small-pool PCR was carried out to quantify the frequency of novel alleles. For this, DNA samples were further diluted to achieve a PCR input of 6.25-50 pg. The quantity of DNA was optimized to achieve amplification in the majority of PCR reactions, but containing predominantly one allele. The 25 ml PCR reaction mix contained 0.4 mM of both forward and reverse primers and 12.5 ml PCR Master Mix (Qiagen w Multiplex, Qiagen). The PCR program consisted of a first denaturation step at 958C for 5 min, followed by 38 cycles at 948C for 30 s, 588C for 30 s, 728C for 30 s and final extension at 728C for 10 min. Each sample was analyzed in 48 replicates and no-template controls (without DNA) were included in order to rule out contamination.
Fragment analysis
Fluorescently labeled PCR products were analyzed by capillary electrophoresis using an ABI 3130XL Genetic Analyser (Life Technologies, Carlsbad, CA, USA), and the results were interpreted by GeneMapper 4.0 software (Life Technologies).
Real-time quantitative PCR
Quantitative RT-PCR was carried out on a ViiA 7 thermocycler (Life Technologies, Foster City, CA, USA) using two endogenous controls (UBC and GAPDH) and analyzed using the ViiA 7 software version 1.2 (Life Technologies). Reactions were performed in the fast mode, in 20 ml total volume, comprising 10 ml 2× TaqMan Fast Universal Master Mix (Life Technologies), 40 ng of cDNA and 1 ml of TaqMan gene expression assays for
and PMS2 (Hs00416527_m1) or 900 nM primer mix and 250 nM probes for UBC (forward: 5 ′ -CGCAGCCGGATTTG-3 ′ ; reverse: 5 ′ -TCAAGTGAC GATACAGCGA-3 ′ ; probe: 6-FAM-TCGCAGTTCTTGTTTGTG-MGB) and GAPDH (forward: 5 ′ -ATG GAA ATC CCA TCA CCA TCT T-3 ′ ; reverse: 5 ′ -CGC CCC ACT TGA TTT TGG-3 ′ ; probe: 6-FAM-CAG GAG CGA GAT CC-MGB). We analysed seven hESC lines and one human fibroblast (HF) sample as a reference.
Immunocytochemistry for MLH1 and MSH2
Human ESCs were cultured in four-well plates for 4 days, fixed with 4% formalin, permeabilized using PBS containing 0.25% Triton X-100 for 10 min and then blocked in 2% normal goat serum, 2% BSA and 0.3% Triton-X for 1 h. The mouse anti-human MLH1 (WH0004292M2, Sigma-Aldrich) or MSH2 (ab52266, Abcam plc, Cambridge, UK) antibody was incubated for 1 h at 1/100 and 1/200 dilution, respectively. After washing with PBS, the secondary Alexa Fluor 488-conjugated goat anti-mouse antibody, diluted 1/500, was incubated for 1 h. Finally, hESCs were mounted with Prolong Gold Antifade reagent containing DAPI (Molecular Probes) and evaluated using an IX-81 fluorescence microscope (Olympus).
Results
Multiplex PCR shows signs of MSI in VUB01 and VUB04
Initially, we studied our hESC lines by conventional PCR for a large number of microsatellites for two different purposes. First, we used the microsatellites to confirm the presence and/or breakpoints of various chromosomal abnormalities that were detected by aCGH during the routine testing of our lines and during a previous study (Spits et al., 2008) . Secondly, we aimed at investigating if our lines displayed uniparental disomy or loss of heterozygosity, which would pass undetected by the aCGH platform we used. In this context, we studied 122 microsatellites spread over all chromosomes, except for the Y chromosome in 10 different in-house derived hESC lines, for 1-11 different passages.
Whilst we did not observe uniparental disomy or loss of heterozygosity in any of our lines, the results revealed unexpected patterns in some of the microsatellites in the lines VUB01 and VUB04. The first striking result that was encountered involved VUB01 at passage 71. This subline carried a monosomy 18 (45, XY, 218), according to the analysis performed by aCGH, but microsatellite D18S1149 on chromosome 18 revealed two alleles instead of one (data not shown). Also, multiplex PCR for microsatellites on chromosome 15 showed a shift in D15S1028 from a homozygous pattern with an allelic fragments of 176 bp at passages 62 and 135 to a heterozygous one (176/178 bp) at passages 251 and 276 (Fig. 1a) . Next, in VUB04 we found that D18S113 did not follow the chromosomal abnormality we knew the line had acquired (46,XX,dup(5)(q14.2q35.3), del(18)(q21.2q23)). The microsatellite D18S113 is located in the deleted region of chromosome 18, and showed a shift from an allele with a fragment length of 187 bp at passages 29 and 66 to a novel allele of 185 bp at passage 117 (Fig. 1b) .
Small pool data suggest MSI in several hESC lines
To gain better insight on the extend of the MSI we observed in VUB01 and VUB04, we performed small-pool PCR for two to seven different microsatellites for both lines at several passages, and calculated the frequency in which each allele was present.
For VUB01, the analysis of D18S1149 revealed several novel alleles that had not been observed in the previous experiments. Next to the two original alleles, with amplified fragment lengths of 164 and 166 bp, we found alleles of 156, 160 and 162 bp. Some of these alleles were found in samples from other passages, but mostly at lower frequencies than in the sample of passage 71 (Fig. 2a) . In the process of testing other microsatellites for this line, passage 71 repeatedly showed a pattern of several novel alleles being present at a low frequency, namely for D18S364, D18S1153 and D18S1154 (data not shown). Additionally, a shift from one to two alleles was observed for microsatellite D15S1028, with the novel allele accounting for 50% of the total at passage 251 (Fig. 2b) .
Similarly, D18S1149 for VUB04 presented a pattern of one to five novel alleles apart from the two original ones, and already from passage 14 (Fig. 2c) . Another microsatellite on chromosome 18 (D18S113), for the same line, appeared shifted from the 187 bp allele at earlier passages (29 and 66) to 185 bp at later passage (117). The small-pool PCR results showed the decrease in frequency of the original allele along with an increase of the novel allele at later passages. Eventually, at passage 117, allele 185 bp accounted for 100% of the total allele frequency. Furthermore, we also detected several additional novel alleles (183, 187, 191 bp) at passage 66 at very low grade (Fig. 2d) .
To study whether MSI is line specific, we carried out small-pool PCR for three additional hESC lines (VUB03, VUB07 and VUB31). We tested VUB03 and VUB31 for D18S364, D18S113, D18S1149 and D15S1028, and VUB07 for D18S364 and D18S1149. VUB07 proved stable for D18S364 and showed a novel allele on a very low frequency for D18S1149, and VUB03 showed no MSI at all (data not shown). Conversely, MSI was found for D18S1149 in passage 42 of VUB31. Whilst conventional PCR revealed only one signal for this microsatellite with a fragment length of 166 bp, the results of the small-pool PCR showed several extra signals with frequencies ranging from 3.6 to 21.4% (Fig. 2e and f) .
Low-grade microsatellite instability in hESC
Bethesda panel testing does not point out any differences Next, we tested 21 of our hESC lines by PCR for CAT25 and the markers of the Bethesda panel, a set of five microsatellites commonly used to identify MSI in cancers and especially in the hereditary non-polyposis colorectal cancer. Special attention was given to the three lines that showed signs of instability after the first set of experiments, for which, next to conventional PCR (Fig. 2g) we also performed small-pool PCR for 48 replicates. Nevertheless, there was no difference in the allelic pattern of the microsatellites on different passages of all 21 lines that we tested.
Clonal hESC lines display identical patterns
In order to study how culture mosaicism is linked to the appearance of the reported novel alleles, we created clonal hESC lines, derived from single cells, and performed PCR for the three microsatellites used above (D18S113, D18S1149 and D15S1028). In total, we studied 28 single-cell lines of both early and late passages of VUB01 and VUB07. However, we did not detect any line carrying a different allelic pattern to the original cells.
No correlation between MSI and MMR gene expression and protein levels
Several studies have pointed out that inactivation or deficiency in the MMR is the main cause of MSI in cancer. For this reason, we addressed the question if there was a possible link between MSI and the MMR gene expression in hESCs. We carried out a gene expression study for seven MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2). Our results indicated that MMR genes were expressed in a higher level in hESCs when compared with HFs, but found no significant difference in the mRNA levels between the different hESC lines and no link between the MSI status and MMR mRNA gene expression ( Fig. 3a  and b; Supplementary data, Fig. S1 ).
To investigate if there was intra-line variability in the expression of MMR genes, we carried out immunocytochemistry for two MMR proteins: MSH2 and MLH1. This would allow us to assess the expression of these genes at the individual cell level, in contrast to the mRNA expression studies, which provided information at the whole culture level. Our first observation was that MSH2 was variably expressed within the cells of different colonies in the majority of the lines we tested. Representative examples can be found in Fig. 3c and the supplemental figures (Supplementary data, Fig. S2 ). Approximately 60 colonies were counted for each replicate and a summary of the percentages of positive cells in the different cell lines we tested are shown in Table I . Conversely, almost all cells were found positive for MLH1, with the most significant variation seen for VUB09 (Fig. 3e and f, overview in Table I ; Supplementary data, Fig. S3) .
Next, we decided to assess if the lack of MSH2 expression of some of the cells was due to a (stable) genetic or epigenetic inactivation of the gene, leading to the mosaic culture of MSH2 positive and negative cells we observed. For this, we created clonal (single-cell-derived) lines for the VUB14 and VUB31. Immunocytochemistry for MSH2 showed that most of the cells in the single-cell colonies were MSH2 positive and none of the colonies were negative (Fig. 3d) .
Discussion
MSI is a form of genome instability commonly found in cancer (Thibodeau et al., 1993; Parsons et al., 1995; Rampino, 1997; Boland and Goel, 2011; Hudler, 2012) in which there is an accumulation of slippage mutations within short tandem repeats during DNA replication, due to loss of the post-replication MMR function. This loss of function is generally due to genetic or epigenetic inactivation of MMR genes, such as MLH1, MSH2, MSH6 and PMS2. In cancer, these mutations often affect homopolymeric sequences located in genes involved, for instance, in cell growth (Parsons et al., 1995) or in cell death (Rampino, 1997; Boland and Goel, 2011) . Mutation of these tracks leads to gene inactivation and may confer a growth advantage to the cells.
In this study, we made two main observations. First, hESCs display (very) low levels of MSI, and secondly, they have a very variable expression of MMR genes, with both inter-and intra-line variability, and which does not seem to correlate with their MSI status.
When looking at the results for the gene expression of the MMR genes, we see that whilst hESCs expressed high levels of mRNA for the common MMR genes, the significant variation between lines and between passages of the same line could not be correlated with the MSI patterns. Next, we carried out immunostainings for two of these genes, MSH2 and MLH1, and found that the hESC colonies themselves also displayed considerable variation. The striking patterns of positive and negative cells set us to generate colonies from single hESC to investigate if this lack of protein expression was due to a stable genetic or epigenetic inactivation of the gene. If this were the case, part of the generated colonies would be homogenously positive and part negative for the protein. The results showed that not only all colonies were positive but that a few of these contained a small fraction of negative cells. This suggests that the MMR genes were not stably inactivated, but rather temporarily, possibly due to the cell-cycle stage or because the cell is undergoing the first steps towards differentiation. Taken together, these results suggested that the MSI we observed in our hESC lines was not caused by inactivation of the MMR, as seen in cancers, and were in fact in line with the low frequency of novel alleles seen in the cells.
In the field of cancer research, it has been suggested that the larger the number of microsatellites studied in a sample, the greater becomes the chance of detecting low-grade MSI (Halford et al., 2002) . In our study, we did not detect any MSI when using the standard panel of microsatellites used in oncogenetics. Conversely, the fact that we studied a very large number of microsatellites leads to the serendipitous finding of a few instances of MSI. In the same line, most novel alleles were identified in chromosome 18, for which we did a more extensive screening of microsatellites. Furthermore, the lower the input of DNA to the PCR reaction (small-pool PCR), the higher the chance is for a low-frequency allele to be detected. The PCR results for VUB31 at passage 42, microsatellite D18S1149, represent a good example of this correlation and underline the differences in both the number and frequencies of the novel alleles (data not shown). Whilst conventional PCR showed the presence of one allele, small-pool PCR revealed four additional alleles with a varying frequency. In addition to this, all the clonal lines that we created from single cells showed the same allelic pattern as the original lines, which further illustrates the rare incidence of this phenomenon in stem cells.
An intriguing question is how some of the novel microsatellite alleles take over the culture. Given that the frequency to which these alleles generate is very low, a shift in genotype of the whole culture implies that the whole culture was taken over by the descent of one single cell.
An interesting example is that of VUB04. The study of the genetic content of VUB04 by aCGH showed a deletion on chromosome 18q21.2q23 as from passage 66 (Spits et al., 2008) . Two of the microsatellites in this region showed the expected allelic shifts, in accordance with the deletion, and one, D18S113, showed an odd pattern. This microsatellite was homozygous at passages 29 and 66, and, at later passages, it appeared to be still homozygous, but for a different allele than before (Fig. 1b) . Analysis by small-pool PCR revealed that this second allele had been present at a low frequency at least as from passage 29, probably in random drift in the culture. Then, a second hit occurred in one of the cells carrying the novel allele for D18S113: the deletion of 18q21.2q23. This deletion confers a selective advantage to the cells, and the mutant cells quickly take over the culture, and so does this novel allele, as a passenger mutation.
The other two cases we observed of culture take-over by cells with a novel microsatellite genotype are more challenging to explain. Both findings were in different sublines of VUB01. In the first case, we knew from the aCGH data that passage 71 of VUB01 carried a monosomy 18, but not all microsatellites on this chromosome showed a single allele as we expected. Conventional PCR showed that D18S1149 retained its heterozygous pattern, and small-pool PCR for the same microsatellite revealed several additional novel alleles at a very low frequency. The presence of one allele for all other microsatellites ensured that all cells in the culture carried only one and the same chromosome 18. For the same line, an allelic shift for a microsatellite on chromosome 15 (D15S1028) was noticed at late passages. Whilst in the early passages, the line was homozygous, it became heterozygous at later passages. Our small-pool PCR results confirmed the presence of a novel allele at the same frequency of the original one. In addition, all other tested microsatellites on chromosome 15 showed two alleles, meaning that the subline carried a normal pair of chromosomes 15 (Fig. 1a) . In both cases, the events seemed to be independent of the chromosomal abnormalities we knew the lines carried. While it is possible that the culture take-over was caused by random drift, it is more likely that they are passenger to other events that go undetected by the genetic screening methods we routinely use in the laboratory. They do not appear to be, by themselves, mutations that could confer a selective advantage.
A limitation of this study is that we only analyzed hESC lines derived and cultured in our laboratory, precluding conclusions on low-grade MSI in other hESC lines in other laboratories. Nevertheless, it is worth keeping in mind that these lines have been derived and cultured in identical conditions as used by the vast majority of laboratories worldwide (Fraga et al., 2011) , and behave identically as other lines concerning their nuclear genome integrity (Spits et al., 2008; Lund et al., 2012; Nguyen et al., 2012) . Furthermore, four of our lines were included in the large study of the international stem cell initiative (Amps et al., 2011) , and their epigenome behaved similarly to the other lines in the study. Finally, these lines differentiate identically to other lines, including NIH approved lines (see for instance, Mfopou et al., 2010) .
The by now well-known genome instability of hESCs raises concerns about the safety of the use of these cells in a clinical setting, particularly given the parallels between the abnormalities found in cancer cells and pluripotent stem cells (Baker et Low-grade microsatellite instability in hESC et al., 2012; Na et al., 2014) . The MSI we found in our hESC lines is present at a very low frequency, much lower than found in cancer cells, making it difficult to predict its potential impact on the differentiation capacity or malignant properties of the cells. It does highlight, however, the mosaic nature of hESC cultures, in line with the works on low-grade chromosomal mosaicism in hPSC (Peterson et al., 2011; Dekel-Naftali et al., 2012; Jacobs et al., 2014) .
To sum up, in this study we show that hESCs show very low-frequency MSI, which does not correlate with inactivation of MMR machinery, as in cancers. These novel alleles sometimes take over the culture, but do not appear to confer selective advantage, and may be rather considered as passenger mutations. In these experiments, the SD represents the variation between different colonies of the same hESC line.
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